|1.||Emons, Günter: 9 articles (01/2008 - 02/2002)|
|2.||Gründker, Carsten: 9 articles (01/2008 - 02/2002)|
|3.||Günthert, Andreas R: 7 articles (01/2008 - 03/2002)|
|4.||Ferrero, Simone: 5 articles (09/2015 - 01/2007)|
|5.||Remorgida, Valentino: 5 articles (09/2015 - 01/2007)|
|6.||Emons, G: 4 articles (11/2001 - 08/2000)|
|7.||Gründker, C: 4 articles (11/2001 - 08/2000)|
|8.||Hou, Ling: 3 articles (07/2015 - 11/2004)|
|9.||Liang, Yan: 3 articles (07/2015 - 11/2004)|
|10.||Wei, Hong: 3 articles (07/2015 - 11/2004)|
|1.||Prostatic Neoplasms (Prostate Cancer)
06/01/2015 - "The improvement in LUTS in men with locally advanced or metastatic prostate cancer after 24-48 weeks suggests that triptorelin is effective in improving LUTS in this subgroup of patients."
05/01/1999 - "Decapeptyl Depot, administered subcutaneously or intramuscularly was effective and safe in the treatment of patients with advanced prostate cancer."
06/01/2015 - "Therefore, multiple, national observational, noninterventional studies were initiated to assess the effectiveness of triptorelin in reducing moderate or severe LUTS [International Prostate Symptom Score (IPSS) >7] in men with prostate cancer starting triptorelin therapy in clinical practice. "
01/01/2015 - "This prospective, noninterventional, open-label, multicentre, Belgian study assessed the prevalence of moderate to severe lower urinary tract symptoms (LUTS) in patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin therapy and its effects on LUTS were evaluated focusing on symptom relief and changes in quality of life (QOL) related to urinary symptoms (November 2006 to May 2010). "
01/01/2015 - "Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study."
06/01/2014 - "This review offers an explanation of the mechanism of action, of the pharmacokinetics and pharmacodynamics of triptorelin and gives the readers a complete overview of the studies on the clinical efficacy, tolerability and safety of this agent in patients with endometriosis. "
02/01/2008 - "A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis."
09/01/2000 - "Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study."
09/01/2015 - "Relieving digestive complaints was not significantly related to either length of triptorelin administration or size of rectal infiltration by deep endometriosis. "
09/01/2015 - "To assess the impact of therapeutic amenorrhoea triggered by triptorelin in the digestive complaints of women with deep endometriosis infiltrating the rectum. "
07/01/2015 - "To evaluate the long-term efficacy of triptorelin 3.75 mg subcutaneously every 6 weeks on the final height in girls with idiopathic central precocious puberty (ICPP). "
12/01/1998 - "Efficacy of the subcutaneous reformulated triptorelin depot in children with central precocious puberty."
11/01/2004 - "The aim of this study was to assess the feasibility of subcutaneous administration of Triptorelin with a prolonged interval (six weeks) for the suppression of pituitary-gonadal axis and clinical signs in girls with idiopathic central precocious puberty (ICPP). "
06/01/1999 - "French study group of Decapeptyl in Precocious Puberty."
11/01/2015 - "An 8-year-old girl who was diagnosed with central precocious puberty was receiving triptorelin acetate treatment uneventfully for 6 months. "
04/01/1998 - "Triptorelin reduces endometriotic lesions and pain to a significantly higher degree than placebo."
04/01/1998 - "Pain symptoms according to both scales were significantly more reduced after 2 months of triptorelin treatment compared to placebo. "
06/01/2014 - "The studies reviewed in the current manuscript demonstrate the efficacy of triptorelin in improving pain symptoms caused by endometriosis. "
02/01/2008 - "The results of 29 cases treated with triptorelin and 25 that received placebo did not show significant differences in pain recurrence (P=1, RR=0.94, 95% CI=0.57-1.55), endometrioma relapse (P=0.67, RR=1.29, 95% CI=0.66-2.50), and pregnancy rate in infertile women (P=0.80, RR=0.81, 95% CI=0.37-1.80). "
01/01/1985 - "After the first week of D-Trp-6-LH-RH administration, major decreases in bone pain and reversal of the signs of prostatism were observed. "
09/01/2015 - "The current study investigates cytotoxic activity of triptorelin as a monotherapy and in treatment combinations with chemotherapeutic agents and inhibitors of the PI3K and the ERK pathways in in vitro models of triple negative breast cancers (TNBC). "
11/01/2015 - "Biological evaluation revealed that TB1, the peptide contains triptorelin sequence, present favorable anti-cancer activity as well as plasma stability. "
05/01/1999 - "Three of the patients treated with triptorelin alone experienced tumor regression compared with four patients in the combination group. "
09/15/1990 - "The effects of Decapeptyl treatment on tumor induction and tumor growth were studied in normal or ovariectomized 6-week-old nude mice inoculated with 10(7) plaque-forming units Py virus (day 0 of experiments). "
01/01/1988 - "Five patients remained stable (SD) on D-Trp-6-LH-RH with no change in tumor size. "
|1.||Gonadotropin-Releasing Hormone (GnRH)
|4.||Drug Therapy (Chemotherapy)